Physician
Hematology
Dr. Peter A. McSweeney, MD
|
|
Give Review
Doctor Peter A. McSweeney, MD practices Hematology. He researched medicine at University of Otago School of Medicine. Peter McSweeney is also published. He has 42 publications published. The lastest publication: "Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.' Peter A. McSweeney, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
- Elevated peri-transplant distress in caregivers of allogeneic blood or marrow transplant patients.
- Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial.
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
- Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
- Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
- Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloab...
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloab...
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot st...
- Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
- Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis.
- Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.
- Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell tran...
- Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of po...
- Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total...
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.
- Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advance...
- Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).
- Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
- Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor c...
- Treatment options for newly diagnosed patients with chronic myeloid leukemia.
- Chronic renal failure after transplantation of a nonrenal organ.
- High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
- Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic ste...
- Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
- Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgraf...
- Hematopoietic cell transplantation for benign hematological disorders and solid tumors.
- High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
- Reduced-intensity allogeneic transplantation for lymphoma.
- Renal dysfunction in allogeneic hematopoietic cell transplantation.
- Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
- Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.
- Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.
- Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells.
- High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review.
- Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitiza...
- Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a m...
Schools
University Of Otago Medical School
Wellington Public Hospital
Hutchinson Cancer Research CenterUniversity
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Stem Cell Transplant
- View All
Doctors Specialties
- Medical Oncology
- Hematology
Accepted Insurances
Education
-
University of Otago School of Medicine
Drug Facts
| NPI NUMBER | 1881678449 | |
| NPPES Provider LastName | MCSWEENEY | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 802181238 | |
| NPPES Provider State | CO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 840.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881678449 |
| Last Name Of The Provider | MCSWEENEY |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
Dr. Robert L. Garcea, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lala A. Cornelius, MD |
|
Dr. Lisa D. Ahrendt, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Todd F. Capizzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle L. Klem, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas J. Kenney III, MD |
|
Dr. Nadine G. Mikhaeel-Kamel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael B. Maris, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Timothy W. Morgan, MD |